Any current/future new fundraising through debt or equity?

Gufic Biosciences completed a preferential equity raising of Rs. 99.99 Crores from Motilal Oswal in October 2023. This amount is planned to be fully utilized for debt repayment by November 2023. Specifically, 50% of the Rs. 99.99 Crores will repay term loans and the remaining will reduce the cash credit (CC) limit. The company is awaiting term loan benefits with no prepayment penalties, expected around April to July next year for further optimization. No mention of any new or upcoming fundraising through additional debt or equity was made for the near future. The focus appears to be on managin

Any current/future capex/capital investment/strategic investment?

Indore facility: Equipment installation complete; validation studies ongoing. Expected to ramp up capacity gradually—25-30% utilization initially, increasing to 70% over time. Indore plant aimed at supporting expansion in injectable/ICU product capacity as Navsari facility nears full capacity by June-July 2024. The design of Indore facility benefits from experience at Navsari, emphasizing efficient, compact layouts and economies of scale. No specific new capital investment numbers detailed, but focus on readiness for expanding domestic and international markets. Ongoing R&D investment in innov

Future growth expectations in sales/revenue/volumes?

Domestic market is the primary driver of growth, contributing around 60-65%, with exports contributing the rest. Sparsh division launched in 12 states, expanding to more states, targeting a run rate of around ₹6-7 Crores per month by end of FY. Contract manufacturing contributes 20-25% of revenue with a stable order book. Planned capacity expansion at Indore facility to handle growing injectable and ICU product demand; expected utilization to grow from 25-30% initially to 70% over a few years. Focus on innovative products like dual chamber bags, Botulinum Toxin, hormone therapies (e.g.

Future growth expectations in earnings/operating earnings/profits/EPS?

The company expects substantial growth from the Sparsh division, targeting 6-7 Crores monthly by the financial year-end, contributing significantly to revenues. Domestic market growth remains strong, supported by new product launches and increased penetration, especially in critical care and fertility segments. International business growth is steady but less aggressive, with secured presence in Germany, Portugal, Canada, and Brazil; Indore facility expansion aimed at supporting future growth. Innovation in R&D, such as room-temperature stable antifungal products and recombinant hormone

Current/ Expected Orderbook/ Pending Orders?

The document does not explicitly mention the current or expected orderbook or pending orders for Gufic Biosciences Limited. However, the company highlights the progress in various divisions: - Indore facility installation is complete with validation studies ongoing. - Strong growth in critical care with multiple product launches such as Dalbavancin and Ceftazidime Avibactam. - Anticipated DCGI approval for Immunocin-Alpha in Q3. - Expected launch of dual-chamber bags post-price approval in Q3. Emphasizes increasing traction in the Sparsh division with plans for geographic expansion and

Gufic BioScienceQ2 FY24Pharmaceuticals & Biotechnology

Gufic BioScience Q2 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹425P/E: 58.0Market Cap: ₹4.3K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

Domestic market is the primary driver of growth, contributing around 60-65%, with exports contributing the rest.
Sparsh division launched in 12 states, expanding to more states, targeting a run rate of around ₹6-7 Crores per month by end of FY.
Contract manufacturing contributes 20-25% of revenue with a stable order book.
Planned capacity expansion at Indore facility to handle growing injectable and ICU product demand; expected utilization to grow from 25-30% initially to 70% over a few years.
Focus on innovative products like dual chamber bags, Botulinum Toxin, hormone therapies (e.g., HMG), and new drug delivery systems expected to augment growth.
New recombinant hormone products targeted for market launch in next 18-24 months to ensure self-reliance and steady supply.
Overall, company expects continued broad-based growth led by domestic branded business and innovative product launches.

Margin guidance

Category 3

The company expects substantial growth from the Sparsh division, targeting 6-7 Crores monthly by the financial year-end, contributing significantly to revenues.
Domestic market growth remains strong, supported by new product launches and increased penetration, especially in critical care and fertility segments.
International business growth is steady but less aggressive, with secured presence in Germany, Portugal, Canada, and Brazil; Indore facility expansion aimed at supporting future growth.
Innovation in R&D, such as room-temperature stable antifungal products and recombinant hormone alternatives, is expected to drive differentiation and market share over the next 18-24 months.
Financial performance shows improved revenues: Q2 FY24 revenue at ₹214.8 Crores up from ₹175.7 Crores. EBITDA improved to ₹39.7 Crores with a slight margin decrease; PAT increased to ₹23.2 Crores from ₹20.2 Crores YoY.
Debt reduction plans and better working capital management may improve profitability and EPS going forward.

See what Gufic BioScience management said on margin guidance — free account, 30 seconds.

Fundraise plans

Gufic Biosciences completed a preferential equity raising of Rs. 99.99 Crores from Motilal Oswal in October 2023.
This amount is planned to be fully utilized for debt repayment by November 2023.
Specifically, 50% of the Rs. 99.99 Crores will repay term loans and the remaining will reduce the cash credit (CC) limit.
The company is awaiting term loan benefits with no prepayment penalties, expected around April to July next year for further optimization.
No mention of any new or upcoming fundraising through additional debt or equity was made for the near future.
The focus appears to be on managing existing debt and optimizing capital structure rather than raising fresh funds.

Order book

The document does not explicitly mention the current or expected orderbook or pending orders for Gufic Biosciences Limited.
However, the company highlights the progress in various divisions:
- Indore facility installation is complete with validation studies ongoing.
- Strong growth in critical care with multiple product launches such as Dalbavancin and Ceftazidime Avibactam.
- Anticipated DCGI approval for Immunocin-Alpha in Q3.
- Expected launch of dual-chamber bags post-price approval in Q3.
Emphasizes increasing traction in the Sparsh division with plans for geographic expansion and growth in branded business.
Mentions that the contract manufacturing business contributes around 20-25% of turnover with typical 90-120 days receivable cycles.
Indicates a robust product pipeline and capacity expansion to support future growth but no specific orderbook figures provided.

See what Gufic BioScience management said on order book — free account, 30 seconds.

Capex plans

Yes

Indore facility: Equipment installation complete; validation studies ongoing. Expected to ramp up capacity gradually—25-30% utilization initially, increasing to 70% over time.
Indore plant aimed at supporting expansion in injectable/ICU product capacity as Navsari facility nears full capacity by June-July 2024.
The design of Indore facility benefits from experience at Navsari, emphasizing efficient, compact layouts and economies of scale.
No specific new capital investment numbers detailed, but focus on readiness for expanding domestic and international markets.
Ongoing R&D investment in innovative products like room-temperature stable antifungals, dual-chamber bags, and recombinant hormone alternatives targeting future launches in 18-24 months.

Track Gufic BioScience — get its next earnings analysis in your feed

Margin guidance

Category 3

The company expects substantial growth from the Sparsh division, targeting 6-7 Crores monthly by the financial year-end, contributing significantly to revenues.
Domestic market growth remains strong, supported by new product launches and increased penetration, especially in critical care and fertility segments.
International business growth is steady but less aggressive, with secured presence in Germany, Portugal, Canada, and Brazil; Indore facility expansion aimed at supporting future growth.
Innovation in R&D, such as room-temperature stable antifungal products and recombinant hormone alternatives, is expected to drive differentiation and market share over the next 18-24 months.
Financial performance shows improved revenues: Q2 FY24 revenue at ₹214.8 Crores up from ₹175.7 Crores. EBITDA improved to ₹39.7 Crores with a slight margin decrease; PAT increased to ₹23.2 Crores from ₹20.2 Crores YoY.
Debt reduction plans and better working capital management may improve profitability and EPS going forward.

Order book

The document does not explicitly mention the current or expected orderbook or pending orders for Gufic Biosciences Limited.
However, the company highlights the progress in various divisions:
- Indore facility installation is complete with validation studies ongoing.
- Strong growth in critical care with multiple product launches such as Dalbavancin and Ceftazidime Avibactam.
- Anticipated DCGI approval for Immunocin-Alpha in Q3.
- Expected launch of dual-chamber bags post-price approval in Q3.
Emphasizes increasing traction in the Sparsh division with plans for geographic expansion and growth in branded business.
Mentions that the contract manufacturing business contributes around 20-25% of turnover with typical 90-120 days receivable cycles.
Indicates a robust product pipeline and capacity expansion to support future growth but no specific orderbook figures provided.

How does Gufic BioScience rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisGufic BioScience

Rev 3Mar 3

See where Gufic BioScience sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does Gufic BioScience rank in Pharmaceuticals & Biotechnology?

Compare Gufic BioScience against every Pharmaceuticals & Biotechnology company (Q2 FY24) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What Gufic BioScience's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

IOL Chemicals (Q1 FY27)
Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…
Innova Captab (Q1 FY27)
The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…
Glenmark Pharma. (Q1 FY27)
Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…
Strides Pharma (Q1 FY27)
markets continue to be broad-based growth drivers, with 17% YoY growth and expansion in B2B and B2C markets including Europe, UK, Nordics, Africa, LATAM, MENA…

Compare:vs Sun Pharmaceutical Industries Ltd vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Gufic BioScience Q2 FY24 Earnings Call Analysis

Revenue guidance

Fundraise plans

Capex plans

Margin guidance

Order book

How does Gufic BioScience rank in Pharmaceuticals & Biotechnology?

Continue your research

What Gufic BioScience's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season